RIMAG GROUP (02522) rose more than 5%. As of press time, the stock was up 4.99% to HK$8.2, with a turnover of HK$16.2266 million.

The increase follows the recent strategic upgrade and global digital intelligence imaging⁺ ecosystem conference held by RIMAG GROUP. At the event, the company officially launched a milestone product: the Brain CT Super Intelligent Agent (Dr. Xiao Jun 2.0). This system was jointly developed by Yinghe Yimai, an AI enterprise incubated by RIMAG GROUP, and Beijing Tiantan Hospital, Capital Medical University. It is described as the world's first medical imaging AI-assisted diagnosis system to achieve "complete intelligence at the examination project level."

Meng Tao, head of the artificial intelligence business, stated that the product is supported by the three foundational pillars of Yinghe Yimai's "Hetu Plan": standard infrastructure, data infrastructure, and model infrastructure. It also utilizes an AI manufacturing factory model characterized by "work as training, use as evolution."

He revealed that, based on the concept of local iteration, the Brain CT Super Intelligent Agent has undergone several months of closed-loop refinement within Tiantan Hospital. The next step involves rapidly replicating the technology to other areas such as abdominal CT, knee joint MR, and aortic CTA. It is anticipated that 12 industry standards and corresponding datasets will be completed by the end of the year.